摘要
目的:研究紫杉醇联合表柔比星治疗晚期乳腺癌的临床疗效,指导临床合理用药。方法:临床乳腺癌患者48例,随机分为实验组24例与对照组24例,分别按两种化疗方案治疗,21～28d为1个周期,两组均至少完成2周期以上评价疗效。结果:实验组与对照组的有效率分别为66.7%和37.5%,两者差异有统计学意义(P=0.004);两组疾病控制率分别为95.8%和70.8%,两者差异有统计学意义(P=0.001);实验组和对照组的平均生存期分别为10.2和6.5月。实验组与对照组严重不良反应发生率差异无统计学意义(P>0.05)。结论:紫杉醇联合表柔比星为临床有效的治疗晚期乳腺癌化疗方案。
Objective： To investigate therapeutic effect of paclitaxel combined with epirubicin in treatment of advanced breast cancer, and provide some knowledge for the rational use of drugs. Methods： Forty eight breast cancer patients were randomly divided into two groups （experimental group and control group）. They were treated by two different chemotherapies. With 21days to 28days as a course,patients underwent at least two coursed and the therapeutical effect was evaluated. Results.The efficacy of the experimental group and control group were 66. 7% and 37. 5%, with significant difference between two groups（P=0. 004）. The disease control rates of the experimental group and control group were 95.8% and 70.8%, with significant difference between two groups（P=0. 001）. Mean survival time was 10.2 months and 6.5 months in experimental group and control group, respectively, without significant differ- ence between two groups （P〉 0. 05）. Conclusions： Paclitaxel combined with epirubicin was an effective chemotherapy in treatment of advanced breast cancer.
出处
《海南医学院学报》
CAS
2012年第5期638-640,共3页
Journal of Hainan Medical University
基金
中国高校医学期刊临床专项资金项目(112210145)~~
关键词
乳腺癌
紫杉醇
表柔比星
不良反应
Paclitaxel
Epirubicin
Breast cancer
Adverse reaction
